217 related articles for article (PubMed ID: 29459949)
21. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H; Söderlund S; Richter J; Saussele S; Koskenvesa P; Stenke L; Mustjoki S; Dimitrijevic A; Stentoft J; Majeed W; Roy L; Wolf D; Dreimane A; Gjertsen BT; Gedde-Dahl T; Ahlstrand E; Markevärn B; Hjorth-Hansen H; Janssen J; Olsson-Strömberg U
Leukemia; 2024 Apr; 38(4):781-787. PubMed ID: 38278960
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey.
Chen H; Zhang Y; Jiang Y; Lin L; Cheng S; Xu X; Zhang X; Lin H; Huang Z; Wang Q; Zhou X; Qu H; Liu X; Li W; Xu N
Leuk Lymphoma; 2023; 64(8):1458-1464. PubMed ID: 37282611
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of BCR::ABL (P210) mRNA levels detected by dPCR and qPCR methods in patients with chronic myeloid leukemia].
Gao HL; Hao Y; Chen WM; Li LD; Wang X; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):906-910. PubMed ID: 38185519
[No Abstract] [Full Text] [Related]
24. Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia.
Fujioka Y; Sugiyama D; Matsumura I; Minami Y; Miura M; Atsuta Y; Ohtake S; Kiyoi H; Miyazaki Y; Nishikawa H; Takahashi N
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885012
[TBL] [Abstract][Full Text] [Related]
25. Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.
Manley PW
Chimia (Aarau); 2019 Aug; 73(7-8):561-570. PubMed ID: 31431216
[TBL] [Abstract][Full Text] [Related]
26. Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
Saglio G; Gale RP
Br J Haematol; 2020 Aug; 190(3):318-327. PubMed ID: 32057102
[TBL] [Abstract][Full Text] [Related]
27. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Winn AN; Atallah E; Cortes J; Deininger MWN; Kota V; Larson RA; Moore JO; Mauro MJ; Oehler VG; Pinilla-Ibarz J; Radich JP; Shah NP; Thompson JE; Flynn KE
JAMA Netw Open; 2023 Dec; 6(12):e2347950. PubMed ID: 38109114
[TBL] [Abstract][Full Text] [Related]
28. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
Saugues S; Lambert C; Daguenet E; Roth-Guepin G; Huguet F; Cony-Makhoul P; Ansah HJ; Escoffre-Barbe M; Turhan A; Rousselot P; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
Haematologica; 2024 May; ():. PubMed ID: 38695126
[TBL] [Abstract][Full Text] [Related]
29. Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients.
Lai X; Jiao X; Zhang H; Lei J
NPJ Syst Biol Appl; 2024 Apr; 10(1):45. PubMed ID: 38678088
[TBL] [Abstract][Full Text] [Related]
30. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
Malagola M; Iurlo A; Bucelli C; Abruzzese E; Bonifacio M; Stagno F; Binotto G; D'Adda M; Lunghi M; Crugnola M; Ferrari ML; Lunghi F; Castagnetti F; Rosti G; Lemoli RM; Sancetta R; Coppi MR; Corsetti MT; De Gobbi M; Romano A; Tiribelli M; Russo Rossi A; Russo S; Defina M; Farina M; Bernardi S; Butturini G; Pellizzeri S; Roccaro AM; Russo D
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):323-331. PubMed ID: 38369436
[TBL] [Abstract][Full Text] [Related]
31. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Machova Polakova K; Albeer A; Polivkova V; Krutska M; Vlcanova K; Curik N; Fabarius A; Klamova H; Spiess B; Waller CF; Brümmendorf TH; Dengler J; Kunzmann V; Burchert A; Belohlavkova P; Mustjoki S; Faber E; Mayer J; Zackova D; Panayiotidis P; Richter J; Hjorth-Hansen H; Kamińska M; Płonka M; Szczepanek E; Szarejko M; Bober G; Hus I; Grzybowska-Izydorczyk O; Wasilewska E; Paczkowska E; Niesiobędzka-Krężel J; Giannopoulos K; Mahon FX; Sacha T; Saußele S; Pfirrmann M
Leukemia; 2024 Feb; 38(2):318-325. PubMed ID: 38129513
[TBL] [Abstract][Full Text] [Related]
32. SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra".
Abruzzese E; Trawinska MM; De Fabritiis P; Bernardi S
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):214-223. PubMed ID: 38151389
[TBL] [Abstract][Full Text] [Related]
33. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs.
Sharf G; Marin C; Bradley JA; Pemberton-Whiteley Z; Bombaci F; Christensen RIO; Gouimi B; Deekes NB; Daban M; Geissler J
Leukemia; 2020 Aug; 34(8):2102-2112. PubMed ID: 32457354
[TBL] [Abstract][Full Text] [Related]
34. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy.
Pagani IS; Shanmuganathan N; Dang P; Saunders VA; Grose R; Kok CH; James J; Tolland M; Braley JA; Altamura HK; Yeung DT; Branford S; Yong ASM; Hughes TP; Ross DM
Blood; 2023 Dec; 142(25):2192-2197. PubMed ID: 37616555
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia.
Costa A; Abruzzese E; Latagliata R; Mulas O; Carmosino I; Scalzulli E; Bisegna ML; Ielo C; Martelli M; Caocci G; Breccia M
J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202280
[TBL] [Abstract][Full Text] [Related]
36. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML.
Millot F; Suttorp M; Ragot S; Leverger G; Dalle JH; Thomas C; Cheikh N; Nelken B; Poirée M; Plat G; Versluys B; Lausen B; Borisevich M
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439257
[TBL] [Abstract][Full Text] [Related]
37. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia.
Nasnas PE; Jabbour EJ; Sasaki K; Issa GC; Masarova L; Short NJ; Haddad FG
Acta Haematol; 2024 Apr; ():. PubMed ID: 38574468
[TBL] [Abstract][Full Text] [Related]
38. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Jabbour E; Haddad FG; Sasaki K; Carter BZ; Alvarado Y; Nasnas C; Nasr L; Masarova L; Daver N; Pemmaraju N; Short NJ; Skinner J; Kadia T; Borthakur G; Garcia-Manero G; Ravandi F; Issa GC; Andreeff M; Kantarjian H
Cancer; 2024 Apr; ():. PubMed ID: 38591430
[TBL] [Abstract][Full Text] [Related]
39. [Posterior reversible encephalopathy syndrome during nilotinib treatment for chronic myeloid leukemia].
Kudo D; Suzuki H; Abe N; Hirai R; Tanimura A; Takeshita M; Miwa A
Rinsho Ketsueki; 2023; 64(12):1514-1518. PubMed ID: 38220151
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia.
Breccia M; Abruzzese E; Annunziata M; Luciano L; Sica S
Front Oncol; 2021; 11():631570. PubMed ID: 33777785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
